USD 1.0785
↑ 0.0085 (0.79%)
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| PAVM | 0.8 | 1.7 | 6.8 | 53.9 | -43.2 | -67.5 | -98.5 | -91.6 | -98.6 | -98.6 |
| S&P 500 | -1.5 | -2.0 | 0.7 | 5.7 | 10.3 | 30.1 | 25.1 | 87.7 | 186.9 | 33067.2 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
š”Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | PAVM |
| name | PAVmed Inc. |
| price | 1.0785 |
| changes percentage | 0.7944 |
| change | 0.0085 |
| day low | 1.03 |
| day high | 1.17 |
| year high | 4.875 |
| year low | 0.6 |
| market cap | 11223302 |
| price avg 50 | 1.22702 |
| price avg 200 | 1.474975 |
| exchange | NASDAQ |
| volume | 132736 |
| avg volume | 62901 |
| open | 1.17 |
| previous close | 1.07 |
| eps | -8.08 |
| pe | -0.13 |
| earnings announcement | 2024-11-12T05:00:00.000+0000 |
| shares outstanding | 10406400 |
| timestamp | 2024-11-15 18:53:53 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001624326 | |||
| revenue | 2452000 | 377000 | 550.40 |
| gross profit | -6900000 | -3237000 | -113.16 |
| gross profit ratio | -2.81 | -8.59 | 67.23 |
| research and development expenses | 14276000 | 25547000 | -44.12 |
| operating expenses | 64827000 | 87690000 | -26.07 |
| interest income | 505000 | 1272000 | -60.30 |
| interest expense | 589000 | 1272000 | -53.69 |
| ebitda | -75742000 | -99412000 | 23.81 |
| ebitdaratio | -30.89 | -246.16 | 87.45 |
| operating income | -68795000 | -90927000 | 24.34 |
| operating income ratio | -28.06 | -241.19 | 88.37 |
| net income | -64175000 | -101294000 | 36.64 |
| net income ratio | -26.17 | -268.68 | 90.26 |
| eps | -9.16 | -17.06 | 46.31 |
Revenue Growth: revenue decreased to 2 million in 2023 from 0 million in 2022 representing a change of 550.4%. This indicates a sales shrinking, which is a negative sign for the company.
Gross Profit: Gross Profit decreased to -7 million in 2023 from -3 million in 2022 representing a change of -113.16%. This indicates a sales profitability decline, which is a negative sign for the company.
Research and Development (R&D) Expenses: R&D Expenses decreased to 14 million in 2023 from 26 million in 2022 representing a change of -44.12%. This shows that the company decreased investment in innovation and product development, which is not a good sign for long-term growth.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to -76 million in 2023 from -99 million in 2022 representing a change of 23.81%. The decrease in EBITDA indicates declined operational efficiency and profitability.
Operating Income: Operating income decreased to -69 million in 2023 from -91 million in 2022 representing a change of 24.34%. The decrease in operating income indicates worse operational performance and decreased profitability.
Operating Expenses: Operating Expenses decreased to 65 million in 2023 from 88 million in 2022 representing a change of -26.07%. The decrease in operating expenses can be attributed to various factors such as improved profitability, cost optimization and financial stability, lower operating expenses can be positive indicators.
Net Income: Net income increased to -64 million in 2023 from -101 million in 2022 representing a change of 36.64%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to -9.16 in 2023 from -9.16 in 2022 representing a change of 46.31%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001624326 | |||
| revenue | 996000000 | 979000 | 101636.47 |
| gross profit | -385000000 | -992000 | -38710.48 |
| gross profit ratio | -0.39 | -1.01 | 61.85 |
| research and development expenses | 1542000000 | 1641000 | 93867.09 |
| operating expenses | 11193000000 | 12692000 | 88089.41 |
| interest income | 70000000 | 110000 | 63536.36 |
| interest expense | -12000000 | 11000 | -109190.91 |
| ebitda | -11578000000 | -14598000 | -79212.23 |
| ebitdaratio | -11.62 | -14.91 | 22.04 |
| operating income | -11578000000 | -13684000 | -84509.76 |
| operating income ratio | -11.62 | -13.98 | 16.83 |
| net income | 64316000000 | -10827000 | 594133.43 |
| net income ratio | 64.57 | -11.06 | 683.89 |
| eps | 6.43 | -1.19 | 640.34 |
Revenue Growth: revenue increased to 996 million in 2024Q3 from 1 million in 2024Q2 representing a change of 101636.47%. This indicates a sales growth, which is a positive sign for the company.
Operating Expenses: Operating Expenses decreased to 11,193 million in 2024Q3 from 13 million in 2024Q2 representing a change of 88089.41%. The decrease in operating expenses can be attributed to various factors such as improved profitability, cost optimization and financial stability, lower operating expenses can be positive indicators.
Net Income: Net income increased to 64,316 million in 2024Q3 from -11 million in 2024Q2 representing a change of 594133.43%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to 6.43 in 2024Q3 from 6.43 in 2024Q2 representing a change of 640.34%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
Gross Profit: Gross Profit decreased to -385 million in 2024Q3 from -1 million in 2024Q2 representing a change of -38710.48%. This indicates a sales profitability decline, which is a negative sign for the company.
Research and Development (R&D) Expenses: R&D Expenses decreased to 1,542 million in 2024Q3 from 2 million in 2024Q2 representing a change of 93867.09%. This shows that the company decreased investment in innovation and product development, which is not a good sign for long-term growth.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to -11,578 million in 2024Q3 from -15 million in 2024Q2 representing a change of -79212.23%. The decrease in EBITDA indicates declined operational efficiency and profitability.
Operating Income: Operating income decreased to -11,578 million in 2024Q3 from -14 million in 2024Q2 representing a change of -84509.76%. The decrease in operating income indicates worse operational performance and decreased profitability.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001624326 | |||
| total assets | 33119000 | 53980000 | -38.65 |
| total liabilities | 57137000 | 43046000 | 32.73 |
| total equity | -24018000 | 10934000 | -319.66 |
| cash and cash equivalents | 19639000 | 39744000 | -50.59 |
| short term investments | 2672000 | 3005000 | -11.08 |
| long term investments | 0 | 0 | NaN |
| total current assets | 24498000 | 43926000 | -44.23 |
| total non current assets | 8620999 | 10054000 | -14.25 |
| total current liabilities | 54177000 | 41200000 | 31.50 |
| total non current liabilities | 2960000 | 1846000 | 60.35 |
| common stock | 9000 | 95000 | -90.53 |
| retained earnings | -294433000 | -228169000 | -29.04 |
| total debt | 48725000 | 36637000 | 32.99 |
Total Assets: Total Assets decreased to 33 million in 2023 from 54 million in 2022 representing a change of -38.65%. Suggesting a decrease in asset holdings.
Total Liabilities: Total Liabilities increased to 57 million in 2023 from 43 million in 2022 representing a change of 32.73%. This indicates an increase in overall liabilities.
Total Equity: Total Equity decreased to -24 million in 2023 from 11 million in 2022 representing a change of -319.66%. This indicates a decrease in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 20 million in 2023 from 40 million in 2022 representing a change of -50.59%. This indicates a decrease in available liquid assets.
Short Term Investments: Short Term Investments decreased to 3 million in 2023 from 3 million in 2022 representing a change of -11.08%. This indicates a decrease in short-term investment holdings.
Total Current Assets: Total Current Assets decreased to 24 million in 2023 from 44 million in 2022 representing a change of -44.23%. This indicates a worsen liquidity position.
Total Current Liabilities: Total Current Liabilities increased to 54 million in 2023 from 41 million in 2022 representing a change of 31.5%. This indicates a higher short-term debt burden.
Common Stock: Common Stock decreased to 0 in 2023 from 0 in 2022 representing a change of -90.53%. This indicates a decrease in ownership interest.
Retained Earnings: Retained Earnings decreased to -294 million in 2023 from -228 million in 2022 representing a change of -29.04%. This indicates an accumulated losses.
Total Debt: Total Debt increased to 49 million in 2023 from 37 million in 2022 representing a change of 32.99%. This indicates an increase in overall debt burden.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001624326 | |||
| total assets | 30550000000 | 39413000 | 77412.50 |
| total liabilities | 39937000000 | 58055000 | 68691.66 |
| total equity | -9387000000 | -18642000 | -50254.04 |
| cash and cash equivalents | 765000000 | 25499000 | 2900.12 |
| short term investments | 0 | 0 | NaN |
| long term investments | 0 | 0 | NaN |
| total current assets | 2130000000 | 30207000 | 6951.35 |
| total non current assets | 28420000000 | 9205999 | 308611.74 |
| total current liabilities | 37557000000 | 53390000 | 70244.63 |
| total non current liabilities | 34430000000 | 4665000 | 737949.30 |
| common stock | 11000000 | 10000 | 109900.00 |
| retained earnings | -256312000000 | -320630000 | -79840.12 |
| total debt | 34929000000 | 50034000 | 69710.53 |
Total Assets: Total Assets increased to 30,550 million in 2024Q3 from 39 million in 2024Q2 representing a change of 77412.5%. Suggesting a growth in asset holdings.
Cash And Cash Equivalents: Cash And Cash Equivalents increased to 765 million in 2024Q3 from 25 million in 2024Q2 representing a change of 2900.12%. This indicates an increase in available liquid assets.
Total Current Assets: Total Current Assets increased to 2,130 million in 2024Q3 from 30 million in 2024Q2 representing a change of 6951.35%. This indicates a better liquidity position.
Common Stock: Common Stock increased to 11 in 2024Q3 from 0 in 2024Q2 representing a change of 109900.0%. This indicates an increase in ownership interest.
Total Liabilities: Total Liabilities increased to 39,937 million in 2024Q3 from 58 million in 2024Q2 representing a change of 68691.66%. This indicates an increase in overall liabilities.
Total Equity: Total Equity decreased to -9,387 million in 2024Q3 from -19 million in 2024Q2 representing a change of -50254.04%. This indicates a decrease in shareholders' equity.
Total Current Liabilities: Total Current Liabilities increased to 37,557 million in 2024Q3 from 53 million in 2024Q2 representing a change of 70244.63%. This indicates a higher short-term debt burden.
Retained Earnings: Retained Earnings decreased to -256,312 million in 2024Q3 from -321 million in 2024Q2 representing a change of -79840.12%. This indicates an accumulated losses.
Total Debt: Total Debt increased to 34,929 million in 2024Q3 from 50 million in 2024Q2 representing a change of 69710.53%. This indicates an increase in overall debt burden.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001624326 | |||
| net change in cash | -20105000 | -37514000 | 46.41 |
| operating cash flow | -52036000 | -70985000 | 26.69 |
| free cash flow | -52278000 | -72525000 | 27.92 |
| capital expenditure | -242000 | -1540000 | 84.29 |
| depreciation and amortization | 2932000 | 2457000 | 19.33 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 11139000 | 19532000 | -42.97 |
| accounts payables | -918000 | -742000 | -23.72 |
| inventory | 0 | 0 | NaN |
| acquisitions net | 0 | -3200000 | 100.00 |
| investments in property plant and equipment | -242000 | -1540000 | 84.29 |
| net cash used for investing activites | 758000 | -4740000 | 115.99 |
| debt repayment | 9921000 | 35227000 | -71.84 |
| common stock issued | 1817000 | 1886000 | -3.66 |
| common stock repurchased | 0 | -366000 | 100.00 |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 31173000 | 38211000 | -18.42 |
| cash at end of period | 19639000 | 39744000 | -50.59 |
| accounts receivables | -44000 | 183000 | -124.04 |
| cash at beginning of period | 39744000 | 77258000 | -48.56 |
Net Change in Cash: Net Change in Cash increased to -20 million in 2023 from -38 million in 2022 representing a change of 46.41%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow increased to -52 million in 2023 from -71 million in 2022 representing a change of 26.69%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to -52 million in 2023 from -73 million in 2022 representing a change of 27.92%. This indicates an increase in cash generated after accounting for capital expenditures.
Stock-Based Compensation: Stock-Based Compensation decreased to 11 million in 2023 from 20 million in 2022 representing a change of -42.97%. This indicates decreased expenses, which is generally considered a positive sign from a financial perspective.
Accounts Receivables: Accounts Receivables decreased to 0 million in 2023 from 0 million in 2022 representing a change of -124.04%. This suggests that the company has been able to collect payments from its customers more efficiently and timely.
Capital Expenditure: Capital Expenditure increased to 0 million in 2023 from -2 million in 2022 representing a change of 84.29%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
Accounts Payables: The absolute value of Accounts Payables increased to 1 million in 2023 from 1 million in 2022 representing a change of -23.72%. This indicates that the company has increased its outstanding obligations to its suppliers.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001624326 | |||
| operating cash flow | -33623017000 | -11656000 | -2.883610e+05 |
| free cash flow | -33622792000 | -11659000 | -2.882849e+05 |
| capital expenditure | 225000 | -3000 | 7.600000e+03 |
| depreciation and amortization | 1127689000 | 305000 | 3.696341e+05 |
| deferred income tax | -459000 | 0 | NaN |
| stock based compensation | 5712150000 | 1904000 | 2.999079e+05 |
| accounts receivables | 45032000 | 0 | NaN |
| accounts payables | -248319000 | -252000 | -9.843929e+04 |
| inventory | 0 | 0 | NaN |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | 225000 | -3000 | 7.600000e+03 |
| net cash used for investing activites | -16179775000 | -3000 | -5.393257e+08 |
| debt repayment | 0 | -209000 | 1.000000e+02 |
| common stock issued | 29797398000 | 551000 | 5.407776e+06 |
| common stock repurchased | 62000000 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 30929664000 | 11622000 | 2.660303e+05 |
| net change in cash | 739464000 | -37000 | 1.998651e+06 |
| cash at end of period | 765000000 | 25499000 | 2.900120e+03 |
| cash at beginning of period | 25536000 | 25536000 | 0.000000e+00 |
Net Change in Cash: Net Change in Cash increased to 739 million in 2024Q3 from 0 million in 2024Q2 representing a change of 1998651.35%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow decreased to -33,623 million in 2024Q3 from -12 million in 2024Q2 representing a change of -288361.02%. This indicates that the company generated less cash from its core business operations.
Free Cash Flow: Free Cash Flow decreased to -33,623 million in 2024Q3 from -12 million in 2024Q2 representing a change of -288284.87%. This indicates a decrease in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure increased to 0 million in 2024Q3 from 0 million in 2024Q2 representing a change of 7600.0%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
Stock-Based Compensation: Stock-Based Compensation increased to 5,712 million in 2024Q3 from 2 million in 2024Q2 representing a change of 299907.88%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables increased to 248 million in 2024Q3 from 0 million in 2024Q2 representing a change of -98439.29%. This indicates that the company has increased its outstanding obligations to its suppliers.
Accounts Receivables: Accounts Receivables increased to 45 in 2024Q3 from 0 million in 2024Q2 representing a change of nan%. This suggests that the company is less capable of collecting payments from its customers.
We save you time by utilizing Generative AI to summarize earnings transcripts. Our summaries provide a clear insight into the company's current performance, future outlook, and overall sentiment expressed during the call. Click on below links to explore more.
Note: The years mentioned below are fiscal years in accounting.
Q3 2024 Earnings call transcript
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2023-12-31 | 2022-12-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 0.34 | 0.06 | 434.09 |
| net income per share | -8.87 | -17.06 | 47.97 |
| operating cash flow per share | -7.2 | -11.95 | 39.80 |
| free cash flow per share | -7.23 | -12.21 | 40.81 |
| cash per share | 3.09 | 7.2 | -57.14 |
| book value per share | -3.32 | 1.84 | -280.38 |
| tangible book value per share | -3.52 | 1.26 | -378.98 |
| shareholders equity per share | -7.44 | -1.63 | -356.62 |
| interest debt per share | 6.19 | 5.88 | 5.32 |
| market cap | 29793969.52 | 42756516 | -30.32 |
| enterprise value | 58879969.52 | 39649516 | 48.50 |
| pe ratio | -0.46 | -0.42 | -9.99 |
| price to sales ratio | 12.15 | 113.41 | -89.29 |
| pocfratio | -0.57 | -0.6 | 4.94 |
| pfcf ratio | -0.57 | -0.59 | 3.33 |
| pb ratio | -0.55 | -4.42 | 87.47 |
| ptb ratio | -0.55 | -4.42 | 87.47 |
| ev to sales | 24.01 | 105.17 | -77.17 |
| enterprise value over ebitda | -0.78 | -0.4 | -94.91 |
| ev to operating cash flow | -1.13 | -0.56 | -102.58 |
| ev to free cash flow | -1.13 | -0.55 | -106.01 |
| earnings yield | -2.15 | -2.37 | 9.08 |
| free cash flow yield | -1.75 | -1.7 | -3.44 |
| debt to equity | -0.82 | -3.48 | 76.38 |
| debt to assets | 1.33 | 0.62 | 114.09 |
| net debt to ebitda | -0.38 | 0.03 | -1328.70 |
| current ratio | 0.45 | 1.07 | -57.59 |
| interest coverage | -116.8 | -71.48 | -63.39 |
| income quality | 0.81 | 0.69 | 17.93 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 12.62 | 108.86 | -88.41 |
| research and ddevelopement to revenue | 5.82 | 67.76 | -91.41 |
| intangibles to total assets | 0.04 | 0.06 | -32.63 |
| capex to operating cash flow | -0.0 | -0.02 | 78.56 |
| capex to revenue | 0.1 | 4.08 | -97.58 |
| capex to depreciation | 0.08 | 0.63 | -86.83 |
| stock based compensation to revenue | 4.54 | 51.81 | -91.23 |
| graham number | 38.55 | 25.01 | 54.13 |
| roic | 7.14 | -3.72 | 291.91 |
| return on tangible assets | -2.02 | -2.0 | -1.01 |
| graham net net | -4.77 | -0.03 | -18332.23 |
| working capital | -29679000 | 2726000 | -1188.74 |
| tangible asset value | -25442000 | 7489000 | -439.72 |
| net current asset value | -32639000 | 880000 | -3808.98 |
| invested capital | -22205000 | 11659000 | -290.45 |
| average receivables | 39000 | 108500 | -64.06 |
| average payables | 2245000 | 3001500 | -25.20 |
| average inventory | 400000 | 2457000 | -83.72 |
| days sales outstanding | 9.08 | 16.46 | -44.83 |
| days payables outstanding | 69.71 | 273.09 | -74.48 |
| days of inventory on hand | 21.04 | 26.36 | -20.19 |
| receivables turnover | 40.2 | 22.18 | 81.26 |
| payables turnover | 5.24 | 1.34 | 291.78 |
| inventory turnover | 17.35 | 13.85 | 25.30 |
| roe | 1.19 | 10.46 | -88.61 |
| capex per share | 0.03 | 0.26 | -87.10 |
ROE: Return on Equity (ROE) decreased to 1.19 on 2023-12-31 from 10.46 on 2022-12-31, representing a change of -88.61%. However, ROE is >= 15%, suggesting that the company has been generating high returns for its shareholders still.
Debt-to-Equity Ratio: Debt-to-Equity Ratio increased to -0.82 on 2023-12-31 from -3.48 on 2022-12-31, representing a change of 76.38%. The debt-to-equity ratio has been increasing, indicating that the company has been relying more on debt financing. Higher leverage may increase financial risk. However, a ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to -0.46 on 2023-12-31 from -0.42 on 2022-12-31, representing a change of -9.99%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio decreased to 0.45 on 2023-12-31 from 1.07 on 2022-12-31, representing a change of -57.59%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Also, it's below 1, indicating potential liquidity issues.
| 2024-09-30 Q3 | 2024-06-30 Q2 | Q/Q change % | |
|---|---|---|---|
| PAVM | |||
| calendar year | 2024 | 2024 | NaN |
| revenue per share | 0.1 | 0.11 | -6.93 |
| net income per share | 6.43 | -1.18 | 643.42 |
| operating cash flow per share | -3.36 | -1.27 | -163.88 |
| free cash flow per share | -3.36 | -1.27 | -163.81 |
| cash per share | 0.08 | 2.79 | -97.26 |
| book value per share | -0.94 | -2.04 | 53.94 |
| tangible book value per share | -0.94 | -2.14 | 56.16 |
| shareholders equity per share | -0.49 | -8.08 | 93.98 |
| interest debt per share | 3.49 | 4.81 | -27.42 |
| market cap | 12306616170 | 6992753.72 | 175890.99 |
| enterprise value | 46470616170 | 31527753.72 | 147295.90 |
| pe ratio | 0.05 | -0.16 | 129.63 |
| price to sales ratio | 12.36 | 7.14 | 72.99 |
| pocfratio | -0.37 | -0.6 | 38.99 |
| pfcf ratio | -0.37 | -0.6 | 38.97 |
| pb ratio | -2.53 | -0.09 | -2572.76 |
| ptb ratio | -2.53 | -0.09 | -2572.76 |
| ev to sales | 46.66 | 32.2 | 44.88 |
| enterprise value over ebitda | -4.01 | -2.16 | -85.84 |
| ev to operating cash flow | -1.38 | -2.7 | 48.90 |
| ev to free cash flow | -1.38 | -2.7 | 48.89 |
| earnings yield | 5.23 | -1.55 | 437.54 |
| free cash flow yield | -2.73 | -1.67 | -63.86 |
| debt to equity | -7.17 | -0.6 | -1105.60 |
| debt to assets | 1.14 | 1.12 | 2.41 |
| net debt to ebitda | -2.95 | -1.68 | -75.57 |
| current ratio | 0.06 | 0.57 | -89.98 |
| interest coverage | 964.83 | -1244 | 177.56 |
| income quality | -1.23 | 0.78 | -257.47 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 6.68 | 7.16 | -6.76 |
| research and ddevelopement to revenue | 1.55 | 1.68 | -7.64 |
| intangibles to total assets | 0 | 0.02 | -100.00 |
| capex to operating cash flow | -0.0 | -0.0 | 97.40 |
| capex to revenue | 0.0 | 0.0 | -92.63 |
| capex to depreciation | 0.0 | 0.01 | -97.97 |
| stock based compensation to revenue | 5.74 | 1.94 | 194.89 |
| graham number | 8.39 | 14.66 | -42.79 |
| roic | -0.41 | 0.46 | -189.29 |
| return on tangible assets | 2.11 | -0.28 | 847.96 |
| graham net net | -3.91 | -3.49 | -12.29 |
| working capital | -35427000000 | -23183000 | -152714.56 |
| tangible asset value | -9387000000 | -19589000 | -47819.75 |
| net current asset value | -37807000000 | -27848000 | -135661.99 |
| invested capital | -32593000000 | -15134000 | -215262.76 |
| average receivables | 8109500 | 143000 | 5570.98 |
| average payables | 233116000 | 1358500 | 17059.81 |
| average inventory | 3491500 | 914500 | 281.79 |
| days sales outstanding | 1.45 | 20.13 | -92.82 |
| days payables outstanding | 30.3 | 56.26 | -46.13 |
| days of inventory on hand | 0.39 | 44.89 | -99.13 |
| receivables turnover | 62.25 | 4.47 | 1292.52 |
| payables turnover | 2.97 | 1.6 | 85.64 |
| inventory turnover | 230.17 | 2.01 | 11379.14 |
| roe | -13.21 | 0.15 | -9121.52 |
| capex per share | 0.0 | 0.0 | -93.14 |
ROE: Return on Equity (ROE) decreased to -13.21 on 2024-09-30 Q3 from 0.15 on 2024-06-30 Q2, representing a change of -9121.52%. Suggesting that the company has not been generating high returns for its shareholders.
Current Ratio: Current Ratio decreased to 0.06 on 2024-09-30 Q3 from 0.57 on 2024-06-30 Q2, representing a change of -89.98%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Also, it's below 1, indicating potential liquidity issues.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to 0.05 on 2024-09-30 Q3 from -0.16 on 2024-06-30 Q2, representing a change of 129.63%. Indicating an increase in the relative valuation of the company's stock.
Debt-to-Equity Ratio: Debt-to-Equity Ratio decreased to -7.17 on 2024-09-30 Q3 from -0.60 on 2024-06-30 Q2, representing a change of -1105.60%. The debt-to-equity ratio has been decreasing, indicating that the company has been relying less on debt financing. A ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
None
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Positive
Publish Date: 2024-11-14 15:49:11
PAVmed Inc. (NASDAQ:PAVM ) Q3 2024 Earnings Call Transcript November 14, 2024 8:30 AM ET Company Participants Matt Riley - Director of IR Lishan Aklog - Chairman and CEO Dennis McGrath - CFO Conference Call Participants Ross Osborn - Cantor Fitzgerald Anthony Vendetti - Maxim Group Ed Woo - Ascendiant Capital Operator Good morning, and welcome to the PAVmed's Third Quarter 2024 Business Update Conference Call. At this time, all lines are in a listen-only mode.
Sentiment: Negative
Publish Date: 2024-11-14 08:01:00
Lucid reports record quarterly EsoGuardĀ® revenue and completes clinical evidence package for imminent submission to formally seek Medicare coverage Veris Health completes pilot program with The Ohio State's James Cancer Hospital and continues pursuit of financing to relaunch development of implantable monitor Ongoing initiatives position PAVmed to preserve Nasdaq listing Conference call and webcast to be held today, November 14 th at 8:30 AM EST NEW YORK , Nov. 14, 2024 /PRNewswire/ -- PAVmed Inc. Ā (NASDAQ: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid") and Veris Health Inc. ("Veris"), and presented financial results for the Company for the three months ended September 30, 2024. Conference Call and Webcast TheĀ webcastĀ will take place on Thursday, November 14, 2024, at 8:30 AM and is accessible in the investor relations section of the Company's website at pavmed.com.
Sentiment: Negative
Publish Date: 2024-11-13 08:01:00
EsoGuardĀ® revenue up 20 percent sequentially Clinical evidence package for Medicare coverage submission complete Direct contracting initiative expanded to multiple programs to drive near-term revenue growth Conference call and webcast to be held today, November 13 th at 8:30 AM EST NEW YORK , Nov. 13, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. Ā (Nasdaq: LUCD)Ā ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ)Ā ("PAVmed"), today provided a business update for the Company and presented financial results for the three months ended September 30, 2024. Conference Call and Webcast The webcast will take place on Wednesday, November 13, 2024, at 8:30 AM and will be accessible in the investor relations section of the Company's website at luciddx.com.
Sentiment: Positive
Publish Date: 2024-11-07 08:01:00
Publication, which once again demonstrates strong EsoGuard performance in a screening population, completes Lucid's clinical evidence package for submission to formally seek Medicare coverage NEW YORK , Nov. 7, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. Ā (Nasdaq: LUCD)Ā ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that the manuscript for its multicenter ESOGUARD BE-1 study has been accepted for publication in The American Journal of Gastroenterology, the official journal of the American College of Gastroenterology (ACG). This is the fourth publication presenting clinical validation data for Lucid's EsoGuardĀ® Esophageal DNA Test, and the second to demonstrate its strong performance in an intended-use screening population.
Sentiment: Negative
Publish Date: 2024-11-05 08:01:00
Industry veterans from leading cancer detection firm join Lucid to support expansion in fully-contracted #CheckYourFoodTube Precancer Testing Events, Concierge Medicine, and Employer Markets NEW YORK , Nov. 5, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. Ā (Nasdaq: LUCD)Ā ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that its commercial team has embarked on an expansion of its direct contracting initiative, focusing on programs designed to drive near-term EsoGuardĀ® Esophageal DNA Test revenue, complementing ongoing efforts in traditional reimbursement. These programs include fully-contracted #CheckYourFoodTube Precancer Testing Events, Concierge Medicine, and Employer Markets.
Sentiment: Neutral
Publish Date: 2024-10-31 08:31:00
Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , Oct. 31, 2024 /PRNewswire/ -- PAVmed Inc. Ā (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Thursday, November 14, 2024, at 8:30 AM ET. During the call,Ā Lishan Aklog, M.D.
Sentiment: Negative
Publish Date: 2024-10-30 08:31:00
Conference Call and Webcast at 8:30AM Eastern Time NEW YORK , Oct. 30, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. Ā (Nasdaq: LUCD)Ā ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a business update conference call and webcast on Wednesday, October 13, 2024, at 8:30 AM ET. During the call,Ā Lishan Aklog, M.D.
Sentiment: Positive
Publish Date: 2024-10-15 07:51:00
Patent covers proprietary method using methylation of the CCNA1 gene to help detect esophageal precancer and cancer NEW YORK , Oct. 15, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. Ā (Nasdaq: LUCD)Ā ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application covering its proprietary method of using methylation of the cyclin-A1 (CCNA1) gene to help detect esophagealĀ precancer and cancer, a key component of its EsoGuardĀ® Esophageal DNA Test . "This patent strengthens the already robust intellectual property portfolio underlying our groundbreaking technologies and will provide strong protection for the CCNA1 methylation assay method which is at the heart of the EsoGuard assay," said Lishan Aklog, M.D.
Sentiment: Negative
Publish Date: 2024-10-10 07:51:00
Grant will fund research to optimize Veris Cancer Care Platform for medically underserved cancer patients, in partnership with an academic cancer center NEW YORK , Oct. 10, 2024 /PRNewswire/ -- PAVmed Inc.Ā (Nasdaq: PAVM) ("PAVmed" or the "Company") a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, and its majority-owned digital health subsidiary Veris Health Inc. ("Veris"), today announced that Veris has been awarded a $1.8 million grant from the National Institute on Minority Health and Health Disparities (NIMHD), an institute of the National Institutes of Health (NIH). The two-year grant will fund research to optimize and validate the Veris Cancer Care Platform for the needs of medically underserved cancer patients, in partnership with an academic cancer center.
Sentiment: Negative
Publish Date: 2024-10-09 08:01:00
NEW YORK , Oct. 9, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. Ā (Nasdaq: LUCD)Ā ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will participate in the 2024 Maxim Healthcare Virtual Summit. Event Details: Date: Tuesday, October 15, 2024 Time: 11:30 AM Eastern Time Format: Fireside Chat with Dennis McGrath , Lucid's Chief Financial Officer Venue: Virtual For more information about the 2024 Maxim Healthcare Virtual Summit and to attend Lucid's fireside chat, please visitĀ https://m-vest.com/events/healthcare-10152024.
Sentiment: Negative
Publish Date: 2024-10-08 07:49:00
Company to showcase EsoGuardĀ® and EsoCheckĀ® at the conference's Innovation Pavilion NEW YORK , Oct. 8, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. Ā (Nasdaq: LUCD)Ā ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that the Company and several of its key executives will be participating in the upcoming The MedTech Conference 2024, the world's foremost annual medical technology event, which will be held October 15-17, 2024, in Toronto, Canada. The MedTech Conference is organized by AdvaMed, the world's leading medical technology association.
Sentiment: Positive
Publish Date: 2024-09-24 08:01:00
Follows the Society's strong endorsement of EsoGuard medical policy coverage by payors NEW YORK , Sept. 24, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. Ā (Nasdaq: LUCD)Ā ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), announced that the American Foregut Society's (AFS) 2024 Annual Meeting, being held from September 26-28, 2024 at the Gaylord Rockies Resort & Convention Center in Aurora, CO, will be highlighting its EsoGuardĀ® Esophageal DNA TestĀ for early detection of esophageal precancer to conference participants.
Sentiment: Neutral
Publish Date: 2024-09-16 16:30:00
Efforts include appointment of seasoned biotech investor Sundeep Agrawal, M.D. to board to replace departing directors NEW YORK , Sept.
Sentiment: Negative
Publish Date: 2024-09-10 07:56:00
Leading experts to discuss advances in technologies to prevent esophageal cancer through esophageal precancer screening NEW YORK , Sept. 10, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. Ā (Nasdaq: LUCD)Ā ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), announced that it will be participating as the sole Diamond Sponsor at the 20th International Society for Diseases of the Esophagus (ISDE) World Congress being held from September 22-24, 2024, at the Edinburgh International Convention Centre in Edinburgh, Scotland.
Sentiment: Negative
Publish Date: 2024-09-03 07:51:00
Collaboration aims to enhance early detection of esophageal cancer in at-risk patients through strategic co-marketing initiatives serving firefighters NEW YORK , Sept. 3, 2024 /PRNewswire/ --Ā Lucid Diagnostics Inc. Ā (Nasdaq: LUCD)Ā ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the execution of a memorandum of understanding (MOU) with Front Line Mobile HealthĀ ("Front Line"), a comprehensive medical care provider for first responders.
Sentiment: Negative
Publish Date: 2024-08-20 08:16:00
Study demonstrates excellent analytical accuracy, repeatability, and reproducibility of the assay NEW YORK , Aug. 20, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. Ā (Nasdaq: LUCD)Ā ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the peer-reviewed publication of an analytical validation study of its EsoGuardĀ®Ā Esophageal DNA test for the diagnosis of esophageal precancer (Barrett's Esophagus or BE) and esophageal adenocarcinoma (EAC) on samples collected non-endoscopically using Lucid's EsoCheckĀ® Esophageal Cell Collection Device. The manuscript, entitled Analytical Validation of a DNA Methylation Biomarker Test for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma from Samples Collected Using EsoCheckĀ®, a Non-Endoscopic Esophageal Cell Collection Device , has been published in the peer-reviewed journal Diagnostics , and is currently available via open access online.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
š”Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright Ā© 2024 Sirius Investors
All rights reserved
